Cannabis
Khiron Appoints Veteran Independent Director Deborah Rosati FCPA, FCA, ICD.D
Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announces that Mark Monaghan has resigned as a director of the Company and that Deborah Rosati FCPA, FCA, ICD.D has been appointed effective immediately to the Board of Directors of the Company. Ms. Rosati has over 30 years of experience in leading and managing high growth companies and joins the Board, effective immediately.
Deborah Rosati is an accomplished corporate director, entrepreneur and FCPA with more than 30 years of experience, including in consumer, cannabis, private equity and venture capital, and has advised over 20 private companies on business strategy and financial growth. Deborah is a past Board member and Chair of the Audit Committee at MedReleaf Corp. (acquired by Aurora Cannabis), the Founder and CEO of Women Get On Board, a member-based company that connects, promotes and empowers women to corporate boards, and is the recipient of multiple finance and leadership awards.
Deborah’s extensive audit and governance experience includes positions as past Chair of the Audit Committee at Sears Canada Inc., a Member of the Department Audit Committee at Correction Services Canada, and at NexJ Systems Inc. where she was a Board member and Chair of the Audit Committee.
“We are very pleased to welcome Deborah. Her experience in finance, corporate strategy, mergers and acquisitions, and governance will be a tremendous asset for the Company. As we continue to expand our operations and execute on our business strategy, Deborah’s appointment to our Board is a valued addition,” said Alvaro Torres, Khiron CEO and Director. “We would also like to thank Mark for his many contributions to Khiron since its founding in 2017 when he led the seed capital round to start the Company. Mark has seen Khiron grow from just an idea to the leading brand in Latin America in the emerging medical cannabis industry. His strategic advice has been invaluable, and we look forward to maintaining that relationship with him as a key advisor going forward. We wish him the best in his future endeavors.”
Mark Monaghan commented, “I am extremely proud of what Khiron has accomplished over the past 3 years and I leave the Company well positioned, and well funded to take advantage of its vast market opportunity, and to be a leading global brand. Now is the right time to transition off the Board. I’m confident that Khiron is prepared to continue its success as it attracts a high caliber, independent director in Deborah Rosati.”
-
Avant2 weeks ago
Avant and IMC Execute BLK MKT™ Trademark Licensing Agreement for the German Medical Cannabis Market
-
StickIt1 week ago
StickIt Technologies Inc. Announces Year-End 2023 Financial Results
-
Cannabis1 week ago
Hemp, Inc. Welcomes USDA Approval of GMO Hemp Strain – A Step Forward in Cannabis Biotechnology
-
Cannabis1 week ago
Right On Brands, Inc. Continues Rollout, Announces 13th Store Opening
-
Cannabis1 week ago
Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
-
Cannabis1 week ago
IM Cannabis and Flora Growth Partner to Bring Vessel Cannabis Accessories to the Israeli Market
-
Cannabis1 week ago
Tilray Brands, Inc. Reports Q3 Fiscal 2024 Financial Results
-
Cannabis1 week ago
Geopulse Exploration, Inc. Acquires 50% of ATC Services